# chronic graft-versus-host disease, or cGVHD FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-graft-versus-host-disease-or-cgvhd

> No upcoming FDA catalysts in chronic graft-versus-host disease, or cGVHD; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2024 | [NIKTIMVO (axatilimab) FDA approval](https://sec-api.dev/pdufa/axatilimab) | SNDX | chronic graft-versus-host disease, or cGVHD | completed, approved | "Niktimvo (axatilimab-csfr) is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm)) |
| Aug 2024 | [Revuforj® (revumenib) FDA approval](https://sec-api.dev/pdufa/revumenib) | SNDX | chronic graft-versus-host disease, or cGVHD | completed, approved | "Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443625/sndx-20260930.htm)) |

## Drugs

- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab) (INCY)
- [Revuforj® (revumenib)](https://sec-api.dev/pdufa/revumenib) (SNDX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-graft-versus-host-disease-or-cgvhd.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "chronic graft-versus-host disease, or cGVHD FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-graft-versus-host-disease-or-cgvhd

```bibtex
@misc{secapidev_indications_chronic_graft_versus_host_disease_or_cgvhd_20261116,
  title        = {chronic graft-versus-host disease, or cGVHD FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-graft-versus-host-disease-or-cgvhd}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_graft_versus_host_disease_or_cgvhd_20261116","title":"chronic graft-versus-host disease, or cGVHD FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-graft-versus-host-disease-or-cgvhd","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
